OS Therapies OSTX Acquired in-process research and development
Acquired in-process research and development at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by OS Therapies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about OS Therapies's acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OS Therapies's acquired in-process research and development?
- OS Therapies (OSTX) reported acquired in-process research and development of $7.35M in Q1 2026.
- How has OS Therapies's acquired in-process research and development changed year-over-year?
- OS Therapies's acquired in-process research and development increased by 461.6% year-over-year, from $1.31M to $7.35M.
- What is the long-term trend for OS Therapies's acquired in-process research and development?
- Over 2 years (2023 to 2025), OS Therapies's acquired in-process research and development has grown at a 125.4% compound annual growth rate (CAGR), from $3.22M to $16.36M.
- What does acquired in-process research and development mean?
- Represents cash outflows related to the acquisition of research and development projects that have not yet reached technological feasibility. This metric is critical for biotech firms as it reflects external investment in future pipeline assets rather than internal development costs.